Oral Dosing of Unasyn (Ampicillin/Sulbactam) for UTIs
Unasyn (ampicillin/sulbactam) can be administered orally at a dose of 375 mg (1 tablet) twice daily for 10 days for urinary tract infections, particularly those caused by E. coli and Proteus species. 1
Evidence and Efficacy
Unasyn is a combination of ampicillin (a bactericidal antibiotic) and sulbactam (a beta-lactamase inhibitor) that provides coverage against many common UTI pathogens. The clinical evidence supporting this dosing regimen comes from a study that demonstrated:
- 24 out of 31 patients (77.4%) achieved complete cure
- 5 patients (16.1%) showed improvement
- Only 2 patients (6.5%) failed treatment 1
The efficacy criteria included:
- Elimination of significant bacteriuria
- Regression of leukocyturia
- Resolution of clinical symptoms 1
Administration and Duration
- Dosage: 375 mg tablet
- Frequency: Twice daily
- Duration: 10 days
- Total daily dose: 750 mg 1
This regimen is considered convenient, non-toxic, and well-tolerated by patients 1.
Parenteral Alternative
If oral therapy is not appropriate or for more severe infections, Unasyn can be administered parenterally:
- Intravenous or intramuscular administration
- Daily dose: 6-9 g
- Duration: 7-10 days 2
Parenteral administration has shown 95% clinical and bacteriological efficacy in acute pyelonephritis cases and excellent results in other urogenital infections 2.
Pathogen Coverage
Unasyn is particularly effective against:
Complete elimination of pathogens was achieved in 57.7% of cases in one study using parenteral administration 2.
Considerations for UTI Treatment
When treating UTIs, it's important to consider:
- Local resistance patterns - avoid empiric therapy if E. coli resistance exceeds 20% 3
- Obtain cultures before starting antibiotics for suspected resistant infections 3
- Treatment duration:
- Uncomplicated UTIs: 3-5 days
- Complicated UTIs/pyelonephritis: 7-14 days 3
Potential Pitfalls and Caveats
- Pain at injection site has been reported with parenteral administration 2
- Cultures should be obtained before starting therapy to ensure appropriate antibiotic selection 3
- Reassess therapy at 48-72 hours based on culture results and clinical response 3
- Consider renal function when dosing antibiotics for UTIs 3
- Avoid treating asymptomatic bacteriuria unless in specific populations (e.g., pregnant women) 3
Alternative Treatment Options
For patients who cannot tolerate Unasyn or in cases of resistance, alternatives include: